The Global Sciatica Treatment Market size is expected to reach $810.4 Million by 2028, rising at a market growth of 3.5% CAGR during the forecast period.
Sciatica is a disorder in which the sciatic nerve, a sizable nerve that travels down the back, becomes inflamed and painful. Herniated discs (bulging discs between the vertebrae) and piriformis syndrome (a muscle strain in the posterior (rear) area of the hip) are only two of the many potential causes of sciatica. In most cases, sciatica treatments relieve pain and stop future nerve damage. Sciatica may be treated in several ways, such as with physical therapy, anti-inflammatory drugs, acupuncture, and steroids.
Disease problems such as osteoarthritis, spondylolisthesis, muscular spasms, and lumbar spinal stenosis are often to blame for sciatica. Across the globe, these medical disorders are becoming far more common. Therefore, the likelihood of developing sciatica may rise if certain medical conditions are more prevalent. This will increase the utilization of expected and current therapies during the projection period.
Pharmaceutical firms are placing more and more emphasis on creating non-steroidal epidural injections based on micropellet technology. This is due mainly to the fact that no epidural steroids are licensed for sciatica treatment. The epidural injection based on micropellet technology aids in lowering pain and inflammation by enabling targeted drug delivery to the injured nerves. Moreover, this cutting-edge technology is anticipated to improve the safety and effectiveness of clonidine. Therefore, throughout the duration of the projection, new pharmaceuticals created using micropellet technology would hit the market and significantly boost its expansion.
If sciatica is not treated, it may result in lower back discomfort that lasts for a long time. Therefore, numerous governmental and non-governmental groups are starting specific efforts to raise public awareness of the illness and prevent diagnostic delays. These campaigns to increase patient knowledge of the condition and safe treatment alternatives will fuel market expansion during the projected period.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Sciatica is a disorder in which the sciatic nerve, a sizable nerve that travels down the back, becomes inflamed and painful. Herniated discs (bulging discs between the vertebrae) and piriformis syndrome (a muscle strain in the posterior (rear) area of the hip) are only two of the many potential causes of sciatica. In most cases, sciatica treatments relieve pain and stop future nerve damage. Sciatica may be treated in several ways, such as with physical therapy, anti-inflammatory drugs, acupuncture, and steroids.
Disease problems such as osteoarthritis, spondylolisthesis, muscular spasms, and lumbar spinal stenosis are often to blame for sciatica. Across the globe, these medical disorders are becoming far more common. Therefore, the likelihood of developing sciatica may rise if certain medical conditions are more prevalent. This will increase the utilization of expected and current therapies during the projection period.
Pharmaceutical firms are placing more and more emphasis on creating non-steroidal epidural injections based on micropellet technology. This is due mainly to the fact that no epidural steroids are licensed for sciatica treatment. The epidural injection based on micropellet technology aids in lowering pain and inflammation by enabling targeted drug delivery to the injured nerves. Moreover, this cutting-edge technology is anticipated to improve the safety and effectiveness of clonidine. Therefore, throughout the duration of the projection, new pharmaceuticals created using micropellet technology would hit the market and significantly boost its expansion.
If sciatica is not treated, it may result in lower back discomfort that lasts for a long time. Therefore, numerous governmental and non-governmental groups are starting specific efforts to raise public awareness of the illness and prevent diagnostic delays. These campaigns to increase patient knowledge of the condition and safe treatment alternatives will fuel market expansion during the projected period.
COVID-19 Impact Analysis
The COVID-19 pandemic had a detrimental effect on expanding the world market for sciatica treatments. One of the main problems facing the healthcare sector was the COVID-19 pandemic. Due to the protracted lockdown in important nations, including the United States, China, Japan, India, and Germany, the COVID-19 pandemic outbreak has resulted in the partial or total suspension of manufacturing facilities. Also, this has resulted in the majority of industrial facilities throughout the globe closing down or suspending these manufacturing operations. This has some impact on the production of drugs for sciatica as well.Market Growth Factors
The increasing rate of overweight or obesity prevalence
Obesity and overweight are primarily caused by an imbalance in energy between calories ingested and burned. Worldwide, there has been a rise in the consumption of calorie-dense foods that are rich in fat and sugar, as well as a rise in physical inactivity due to the sedentary nature of many occupations, evolving transportation options, and escalating urbanization. Much pressure is applied when someone is overweight, especially if they like to carry their extra pounds around their midsection. One of the most typical causes of sciatica is being overweight. As a result, it is expected that the incidence of sciatica will increase along with the increased prevalence of obesity or overweight. This would encourage the market for sciatica treatments to expand.Growing proportion of aging population
To make sure that their social and health systems are ready to benefit from this demographic transformation, all nations must overcome significant obstacles. Eighty percent of senior citizens will reside in low- and middle-income countries by 2050. The population is aging considerably more quickly than in the past. In 2020, there will be more persons over 60 than under five-year-olds. The percentage of people over 60 in the globe will increase from 12% to 22% between 2015 and 2050. Osteoarthritis, as well as back and neck discomfort, are common ailments among older people. People are more prone to many conditions at once as they age.Market Restraining Factor
Lack of awareness regarding condition
Sciatica is often assumed to be regular back pain because not enough people know about it. Even though sciatica usually goes away on its own, it can cause permanent damage to the nerve that it affects. Sciatica and lower back pain are both types of back pain, and they are sometimes mistaken for each other before a correct diagnosis is made. The confusion comes from many of the symptoms being the same. But low back pain and sciatica are not the same things at all.Type Outlook
Based on type, the sciatica treatment market is segmented into acute sciatica, chronic sciatica and others. The chronic sciatica segment dominated the sciatica treatment market with maximum revenue share in 2021. Chronic sciatica is characterized by chronic sciatic nerve pain that lasts longer than 8 weeks and typically does not go away on its own. Depending on the underlying reason, chronic sciatica may need nonsurgical or surgical treatment. The expansion of this market may be attributed to the rise in chronic sciatica cases, changes in lifestyle, and an increase in spinal tumor and herniated disc instances.Drug Class Outlook
By drug class, the sciatica treatment market is fragmented into non-steroidal anti-inflammatory drugs, steroids, antidepressants and others. The non-steroidal anti-inflammatory drug (NSAIDs) segment held the highest revenue share in the sciatica treatment market in 2021. To treat sciatica, non-steroidal anti-inflammatory medicines (NSAIDs) are among the most often given drugs. The items are receiving approvals, which is opening up significant market potential. The most popular class of pharmaceuticals, pain relievers, and anti-inflammatory treatments are the most efficient drugs.Distribution Channel Outlook
On the basis of distribution channel, the sciatica treatment market is bifurcated into hospital pharmacies, retail & specialty pharmacies and online providers. The hospital pharmacies segment covered a considerable revenue share in the sciatica treatment market in 2021. Over the projection period, the category is likely to grow. Hospitals handle a variety of patients who exhibit sciatica symptoms, making them the dominant player in this industry. Homecare is a medical service that provides care inside private residences and helps people with sciatica.Regional Outlook
Region wise, the sciatica treatment market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region led the sciatica treatment market by generating maximum revenue share in 2021. The presence of many significant companies, including Amneal Pharmaceuticals LLC, Abbott, and Johnson & Johnson, as well as improvements in the region's pharmaceutical formulation manufacturing technology, are the key factors driving the growth of the market. The demand for drugs used to treat sciatica is also expected to rise in the area due to the condition's prevalence, changes in human lifestyle, and an increase in the number of older people.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Sorrento Therapeutics, Inc., Alkem Laboratories Ltd., Amneal Pharmaceuticals, Inc., Aurobindo Pharma Limited, Novartis AG, and Cadila Healthcare Ltd. (Zydus Cadila)
Scope of the Study
By Type
- Chronic
- Acute
- Others
By Distribution Channel
- Retail & Specialty Pharmacies
- Hospital Pharmacies
- Online Providers
By Drug Class
- Non-Steroidal anti-inflammatory
- Steroids
- Antidepressants
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Sciatica Treatment Market, by Type
1.4.2 Global Sciatica Treatment Market, by Distribution Channel
1.4.3 Global Sciatica Treatment Market, by Drug Class
1.4.4 Global Sciatica Treatment Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Sciatica Treatment Market by Type
3.1 Global Chronic Market by Region
3.2 Global Acute Market by Region
3.3 Global Others Market by Region
Chapter 4. Global Sciatica Treatment Market by Distribution Channel
4.1 Global Retail & Specialty Pharmacies Market by Region
4.2 Global Hospital Pharmacies Market by Region
4.3 Global Online Providers Market by Region
Chapter 5. Global Sciatica Treatment Market by Drug Class
5.1 Global Non-Steroidal anti-inflammatory Market by Region
5.2 Global Steroids Market by Region
5.3 Global Antidepressants Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Sciatica Treatment Market by Region
6.1 North America Sciatica Treatment Market
6.1.1 North America Sciatica Treatment Market by Type
6.1.1.1 North America Chronic Market by Country
6.1.1.2 North America Acute Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Sciatica Treatment Market by Distribution Channel
6.1.2.1 North America Retail & Specialty Pharmacies Market by Country
6.1.2.2 North America Hospital Pharmacies Market by Country
6.1.2.3 North America Online Providers Market by Country
6.1.3 North America Sciatica Treatment Market by Drug Class
6.1.3.1 North America Non-Steroidal anti-inflammatory Market by Country
6.1.3.2 North America Steroids Market by Country
6.1.3.3 North America Antidepressants Market by Country
6.1.3.4 North America Others Market by Country
6.1.4 North America Sciatica Treatment Market by Country
6.1.4.1 US Sciatica Treatment Market
6.1.4.1.1 US Sciatica Treatment Market by Type
6.1.4.1.2 US Sciatica Treatment Market by Distribution Channel
6.1.4.1.3 US Sciatica Treatment Market by Drug Class
6.1.4.2 Canada Sciatica Treatment Market
6.1.4.2.1 Canada Sciatica Treatment Market by Type
6.1.4.2.2 Canada Sciatica Treatment Market by Distribution Channel
6.1.4.2.3 Canada Sciatica Treatment Market by Drug Class
6.1.4.3 Mexico Sciatica Treatment Market
6.1.4.3.1 Mexico Sciatica Treatment Market by Type
6.1.4.3.2 Mexico Sciatica Treatment Market by Distribution Channel
6.1.4.3.3 Mexico Sciatica Treatment Market by Drug Class
6.1.4.4 Rest of North America Sciatica Treatment Market
6.1.4.4.1 Rest of North America Sciatica Treatment Market by Type
6.1.4.4.2 Rest of North America Sciatica Treatment Market by Distribution Channel
6.1.4.4.3 Rest of North America Sciatica Treatment Market by Drug Class
6.2 Europe Sciatica Treatment Market
6.2.1 Europe Sciatica Treatment Market by Type
6.2.1.1 Europe Chronic Market by Country
6.2.1.2 Europe Acute Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Sciatica Treatment Market by Distribution Channel
6.2.2.1 Europe Retail & Specialty Pharmacies Market by Country
6.2.2.2 Europe Hospital Pharmacies Market by Country
6.2.2.3 Europe Online Providers Market by Country
6.2.3 Europe Sciatica Treatment Market by Drug Class
6.2.3.1 Europe Non-Steroidal anti-inflammatory Market by Country
6.2.3.2 Europe Steroids Market by Country
6.2.3.3 Europe Antidepressants Market by Country
6.2.3.4 Europe Others Market by Country
6.2.4 Europe Sciatica Treatment Market by Country
6.2.4.1 Germany Sciatica Treatment Market
6.2.4.1.1 Germany Sciatica Treatment Market by Type
6.2.4.1.2 Germany Sciatica Treatment Market by Distribution Channel
6.2.4.1.3 Germany Sciatica Treatment Market by Drug Class
6.2.4.2 UK Sciatica Treatment Market
6.2.4.2.1 UK Sciatica Treatment Market by Type
6.2.4.2.2 UK Sciatica Treatment Market by Distribution Channel
6.2.4.2.3 UK Sciatica Treatment Market by Drug Class
6.2.4.3 France Sciatica Treatment Market
6.2.4.3.1 France Sciatica Treatment Market by Type
6.2.4.3.2 France Sciatica Treatment Market by Distribution Channel
6.2.4.3.3 France Sciatica Treatment Market by Drug Class
6.2.4.4 Russia Sciatica Treatment Market
6.2.4.4.1 Russia Sciatica Treatment Market by Type
6.2.4.4.2 Russia Sciatica Treatment Market by Distribution Channel
6.2.4.4.3 Russia Sciatica Treatment Market by Drug Class
6.2.4.5 Spain Sciatica Treatment Market
6.2.4.5.1 Spain Sciatica Treatment Market by Type
6.2.4.5.2 Spain Sciatica Treatment Market by Distribution Channel
6.2.4.5.3 Spain Sciatica Treatment Market by Drug Class
6.2.4.6 Italy Sciatica Treatment Market
6.2.4.6.1 Italy Sciatica Treatment Market by Type
6.2.4.6.2 Italy Sciatica Treatment Market by Distribution Channel
6.2.4.6.3 Italy Sciatica Treatment Market by Drug Class
6.2.4.7 Rest of Europe Sciatica Treatment Market
6.2.4.7.1 Rest of Europe Sciatica Treatment Market by Type
6.2.4.7.2 Rest of Europe Sciatica Treatment Market by Distribution Channel
6.2.4.7.3 Rest of Europe Sciatica Treatment Market by Drug Class
6.3 Asia Pacific Sciatica Treatment Market
6.3.1 Asia Pacific Sciatica Treatment Market by Type
6.3.1.1 Asia Pacific Chronic Market by Country
6.3.1.2 Asia Pacific Acute Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Sciatica Treatment Market by Distribution Channel
6.3.2.1 Asia Pacific Retail & Specialty Pharmacies Market by Country
6.3.2.2 Asia Pacific Hospital Pharmacies Market by Country
6.3.2.3 Asia Pacific Online Providers Market by Country
6.3.3 Asia Pacific Sciatica Treatment Market by Drug Class
6.3.3.1 Asia Pacific Non-Steroidal anti-inflammatory Market by Country
6.3.3.2 Asia Pacific Steroids Market by Country
6.3.3.3 Asia Pacific Antidepressants Market by Country
6.3.3.4 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Sciatica Treatment Market by Country
6.3.4.1 China Sciatica Treatment Market
6.3.4.1.1 China Sciatica Treatment Market by Type
6.3.4.1.2 China Sciatica Treatment Market by Distribution Channel
6.3.4.1.3 China Sciatica Treatment Market by Drug Class
6.3.4.2 Japan Sciatica Treatment Market
6.3.4.2.1 Japan Sciatica Treatment Market by Type
6.3.4.2.2 Japan Sciatica Treatment Market by Distribution Channel
6.3.4.2.3 Japan Sciatica Treatment Market by Drug Class
6.3.4.3 India Sciatica Treatment Market
6.3.4.3.1 India Sciatica Treatment Market by Type
6.3.4.3.2 India Sciatica Treatment Market by Distribution Channel
6.3.4.3.3 India Sciatica Treatment Market by Drug Class
6.3.4.4 South Korea Sciatica Treatment Market
6.3.4.4.1 South Korea Sciatica Treatment Market by Type
6.3.4.4.2 South Korea Sciatica Treatment Market by Distribution Channel
6.3.4.4.3 South Korea Sciatica Treatment Market by Drug Class
6.3.4.5 Singapore Sciatica Treatment Market
6.3.4.5.1 Singapore Sciatica Treatment Market by Type
6.3.4.5.2 Singapore Sciatica Treatment Market by Distribution Channel
6.3.4.5.3 Singapore Sciatica Treatment Market by Drug Class
6.3.4.6 Malaysia Sciatica Treatment Market
6.3.4.6.1 Malaysia Sciatica Treatment Market by Type
6.3.4.6.2 Malaysia Sciatica Treatment Market by Distribution Channel
6.3.4.6.3 Malaysia Sciatica Treatment Market by Drug Class
6.3.4.7 Rest of Asia Pacific Sciatica Treatment Market
6.3.4.7.1 Rest of Asia Pacific Sciatica Treatment Market by Type
6.3.4.7.2 Rest of Asia Pacific Sciatica Treatment Market by Distribution Channel
6.3.4.7.3 Rest of Asia Pacific Sciatica Treatment Market by Drug Class
6.4 LAMEA Sciatica Treatment Market
6.4.1 LAMEA Sciatica Treatment Market by Type
6.4.1.1 LAMEA Chronic Market by Country
6.4.1.2 LAMEA Acute Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Sciatica Treatment Market by Distribution Channel
6.4.2.1 LAMEA Retail & Specialty Pharmacies Market by Country
6.4.2.2 LAMEA Hospital Pharmacies Market by Country
6.4.2.3 LAMEA Online Providers Market by Country
6.4.3 LAMEA Sciatica Treatment Market by Drug Class
6.4.3.1 LAMEA Non-Steroidal anti-inflammatory Market by Country
6.4.3.2 LAMEA Steroids Market by Country
6.4.3.3 LAMEA Antidepressants Market by Country
6.4.3.4 LAMEA Others Market by Country
6.4.4 LAMEA Sciatica Treatment Market by Country
6.4.4.1 Brazil Sciatica Treatment Market
6.4.4.1.1 Brazil Sciatica Treatment Market by Type
6.4.4.1.2 Brazil Sciatica Treatment Market by Distribution Channel
6.4.4.1.3 Brazil Sciatica Treatment Market by Drug Class
6.4.4.2 Argentina Sciatica Treatment Market
6.4.4.2.1 Argentina Sciatica Treatment Market by Type
6.4.4.2.2 Argentina Sciatica Treatment Market by Distribution Channel
6.4.4.2.3 Argentina Sciatica Treatment Market by Drug Class
6.4.4.3 UAE Sciatica Treatment Market
6.4.4.3.1 UAE Sciatica Treatment Market by Type
6.4.4.3.2 UAE Sciatica Treatment Market by Distribution Channel
6.4.4.3.3 UAE Sciatica Treatment Market by Drug Class
6.4.4.4 Saudi Arabia Sciatica Treatment Market
6.4.4.4.1 Saudi Arabia Sciatica Treatment Market by Type
6.4.4.4.2 Saudi Arabia Sciatica Treatment Market by Distribution Channel
6.4.4.4.3 Saudi Arabia Sciatica Treatment Market by Drug Class
6.4.4.5 South Africa Sciatica Treatment Market
6.4.4.5.1 South Africa Sciatica Treatment Market by Type
6.4.4.5.2 South Africa Sciatica Treatment Market by Distribution Channel
6.4.4.5.3 South Africa Sciatica Treatment Market by Drug Class
6.4.4.6 Nigeria Sciatica Treatment Market
6.4.4.6.1 Nigeria Sciatica Treatment Market by Type
6.4.4.6.2 Nigeria Sciatica Treatment Market by Distribution Channel
6.4.4.6.3 Nigeria Sciatica Treatment Market by Drug Class
6.4.4.7 Rest of LAMEA Sciatica Treatment Market
6.4.4.7.1 Rest of LAMEA Sciatica Treatment Market by Type
6.4.4.7.2 Rest of LAMEA Sciatica Treatment Market by Distribution Channel
6.4.4.7.3 Rest of LAMEA Sciatica Treatment Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Johnson & Johnson
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental &Regional Analysis
7.2.4 Research & Development Expenses
7.3 Teva Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sun Pharmaceutical Industries Ltd.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Regional & Segmental Analysis
7.4.4 Research & Development Expenses
7.5 Sorrento Therapeutics, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental Analysis
7.5.4 Research & Development Expenses
7.6 Alkem Laboratories Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Amneal Pharmaceuticals, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental
7.7.4 Research & Development Expenses
7.8 Aurobindo Pharma Limited
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expense
7.9 Novartis AG
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.10. Cadila Healthcare Ltd. (Zydus Cadila)
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expense
Companies Mentioned
- Abbott Laboratories
- Johnson & Johnson
- Teva Pharmaceutical Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sorrento Therapeutics, Inc.
- Alkem Laboratories Ltd.
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma Limited
- Novartis AG
- Cadila Healthcare Ltd. (Zydus Cadila)
Methodology
LOADING...
